Table 6

Enriched X. laevis pathways due to cyclopamine treatment using SEPEA_NT2*

KEGG pathway ID

Pathway description

P-value

[path:xla00930]

Caprolactam degradation

0.006

[path:xla03030]

DNA replication

0.011

[path:xla00480]

Glutathione metabolism

0.016

[path:xla00561]

Glycerolipid metabolism

0.023

[path:xla03010]

Ribosome

0.045

[path:xla00982]

Drug metabolism - cytochrome P450

0.057

[path:xla00983]

Drug metabolism - other enzymes

0.057

[path:xla04012]

ErbB signaling

0.067

[path:xla03060]

Protein export

0.072

[path:xla00562]

Inositol phosphate metabolism

0.086

[path:xla04914]

Progesterone-mediated oocyte maturation

0.087

[path:xla04020]

Calcium signaling pathway

0.089

Enriched KEGG [44] pathways (with P-value ≤ 0.1) due to cyclopamine treatment of developing X. laevis, designed to inhibit SHH signaling, using microarray data from GEO [45] [GEO:GSE8293]. P-values were obtained using the SEPEA_NT2* analysis with 1,000 randomizations to compute significance.

Thomas et al. Genome Biology 2009 10:R44   doi:10.1186/gb-2009-10-4-r44